Track market-moving stories before they get noisy

The market expects DexCom (DXCM - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 30. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis medical device company is expected to post quarterly earnings of $0.61 per share in its upcoming report, which represents a year-over-year change of +27.1%.

Revenues are expected to be $1.3 billion, up 11.9% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.07% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for DexCom?For DexCom, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.36%.

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination makes it difficult to conclusively predict that DexCom will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that DexCom would post earnings of $0.47 per share when it actually produced earnings of $0.56, delivering a surprise of +19.15%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

DexCom doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th.

Po týdnech zvýšené volatility v sektoru umělé inteligence hledají investoři čím dál častěji příležitosti mimo nejpopulárnější technologické tituly. Analytici Goldman Sachs proto sestavili seznam společností, které mohou nabídnout atraktivní růst bez přímé závislosti na AI boomu. Mezi favority zařadili firmy těžící ze silných spotřebitelských výdajů, rozmachu cestovního ruchu, zábavního průmyslu či finančních služeb, ale také kvalitní společnosti, jejichž ocenění podle banky neodpovídá jejich fundamentům.

Goldman Sachs se zaměřil na akcie mimo sektor s umělou inteligencí poté, co s ním týdny zmítá volatilita. „Zatímco mnoho správců fondů si zachovalo býčí fundamentální pohled na komplex AI infrastruktury, nedávná volatilita ztížila držení tohoto názoru,“ napsali analytici Goldman Sachs v čele s Benem Sniderem po pátečním uzavření trhu. „Také naše rozhovory s investory se točily kolem výzvy najít investiční příležitosti, které nejsou spojeny s umělou inteligencí.“

Goldman Sachs se tak zaměřil na alternativní investiční témata, mezi nimiž jsou společnosti vázané na spotřebitelské výdaje a vysoce ziskové společnosti obchodované s výraznými slevami. V tabulce, kterou sestavila CNBC, najdete pět společností z obou těchto skupin:

Sázky na štědré výdaje spotřebitelů

Formula One Group Series, akcie vlastněné společností Liberty Media, odrážejí ekonomický zájem o komerční provoz mistrovství světa Formule 1 FIA. Morgan Stanley začátkem tohoto měsíce znovu označila Formuli 1 za nejlepší volbu s cílovou cenou 120 dolarů (což implikuje 21% nárůst oproti pondělnímu uzavření). Analytik Sean Differley označil tento sport za „nedostatečně monetizovaný“ a zdůraznil růstové příležitosti v USA a Číně. Podle údajů LSEG ji 11 ze 13 analytiků, kteří se zabývají Formulí 1, hodnotí doporučením nákup nebo silný nákup.

Live Nation se dostal mezi tipy Goldman Sachs, protože poptávka po živých akcích nadále roste. UBS ve zprávě zveřejněné v pondělí zvýšila cílovou cenu pro Live Nation na 208 dolarů, což naznačuje 15% růst. „Očekáváme, že poptávka po živých akcích zůstane celosvětově silná s dvojciferným růstem fanoušků,“ napsal analytik UBS Batya Levi.

U Walt Disney má 36 analytiků ze 40 doporučení „koupit“ s průměrnou cílovou cenou 129 USD, což naznačuje potenciální zhodnocení o 34 %. Příjmy z reklamy by mělo podpořit jak fotbalové mistrovství světa, tak vyšší výdaje na politické kampaně. Pokles příjmů z tradiční televizní distribuce se zmírňuje díky pomalejšímu odlivu předplatitelů placené televize a ziskovost streamovacích platforem se dále zlepšuje. Na druhou stranu investory znepokojuje konsolidace v tomto sektoru i dlouhodobé dopady AI.

Las Vegas Sands doporučuje 15 analytiků z 21 kupovat s průměrnou 12měsíční cílovou cenou 65,4 USD, což naznačuje potenciál růstu o 44 %. Investice společnosti Sands do neherních aktivit v Macau a Singapuru by měly podpořit návratnost vloženého kapitálu. Oživení cestovního ruchu vedlo k růstu návštěvnosti i příjmů z masového a VIP segmentu. A rozhodnutí Sands upřednostnit návrat kapitálu akcionářům namísto snahy o získání licence v New Yorku se projevilo navýšením programu zpětného odkupu akcií o 1,3 miliardy dolarů a zvýšením dividendy o 20 %.

U hotelového řetězce Marriott International v pátek Morgan Stanley zvýšila cenový cíl z 353 dolarů na 380 dolarů, což oproti pondělnímu uzavření obchodu znamená nárůst o přibližně 4 %. „Společnost Marriott za posledních 10 let transformovala své podnikání, zbavila se vlastněných nemovitostí, odkoupila časově sdílená aktiva a změnila manažerské smlouvy tak, aby byly variabilnější,“ napsal analytik Morgan Stanley Stephen Grambling. „Domníváme se, že tyto změny dramaticky snižují cykličnost, což by mělo vést k dalšímu přehodnocení ratingu.“

Zlevněné hvězdy

Výrobce zařízení pro sledování hladiny cukru v krvi Dexcom vstupuje do výsledkové sezony s potenciálem pozitivního překvapení, domnívá se Bloomberg. Silná adopce senzoru G7 15 Day, růst dodávek a možné získávání podílu na trhu vytvářejí prostor pro překonání odhadů i případné zvýšení výhledu. Z 27 analytiků, kteří akcii pokrývají, jich má 24 nákupní doporučení. Průměrná cílová cena 86 USD naznačuje růst o 15 %.

Akcie MSCI nabízejí podle Goldmanů silný růst zisků, když jejich návratnost v poslední době zaostávala a nyní se obchodují „s velkou slevou“. Jefferies ji začala sledovat s doporučením nákup a stanovila u ní cenový cíl 760 dolarů, což znamená téměř 22% růst oproti pondělnímu uzavření. Analytik Surinder Thind uvedl, že tento globální poskytovatel indexů je obzvláště atraktivní díky „silné konkurenční výhodě, rozšiřování klientské základny, rostoucí expozici na soukromé trhy, viditelně opakujícím se výnosům a omezenému riziku narušení umělé inteligence“.

U Visy má 48 analytiků, kteří tuto platební společnost pokrývá, 46 nákupní doporučení, přičemž průměrná cílová cena se pohybuje o 14 % nad současnou tržní cenou. Rozdělení platebního ekosystému Visy na samostatné služby by jí mohlo zvýšit výnosy na více než 15,4 miliardy dolarů do roku 2027 oproti 10,8 miliardám dolarů v roce 2025. Tyto služby by tak tvořily přibližně 31 % celkových tržeb společnosti. Přestože tato strategie může působit riskantně, mohla by tím rozšířit své postavení napříč alternativními platebními řešeními, jako jsou digitální peněženky, domácí platební schémata nebo převody z účtu na účet.

Stavební společnost Sterling Infrastructures pokrývá jen 8 analytiků, zato všichni u ní mají nákupní doporučení s průměrnou cílovou cenou 953 USD, což naznačuje růst o 37 %. Firma má ale zároveň velmi silnou divizi E-Infrastructure Solutions, která se zaměřuje na specializovanou infrastrukturní výstavbu pro kritická odvětví a která by si mohla zapsat raketový růst díky boomu AI infrastruktury. I přes pokles v posledních týdnech si tato akcie za letošní rok připsala již 118% růst. Hlavním omezením dalšího růstu nebudou zakázky ani poptávka, ale výrobní a realizační kapacity společnosti. Společnost zakončila první čtvrtletí roku 2026 s čistou hotovostí 224 milionů USD a nadále stabilně generuje silný cash flow.

Booking sleduje 41 analytiků, přičemž 39 z nich ho doporučuje nakupovat s průměrnou cílovou cenou 221 USD, která by mohla vynést dalších 24 %. Poptávka po cestování zůstává navzdory ekonomickým a geopolitickým výkyvům velmi odolná. Zároveň firma intenzivně investuje do AI, kterou chce využít při plánování cest, personalizaci nabídek i zákaznické podpoře, aby si udržela konkurenceschopnost v rychle se měnícím prostředí cestovního ruchu.

16.7.2026 22:00

Negativní sentiment se před koncem obchodní seance ještě více prohloubil. Může za to silný pokles technologického giganta Google, u kterého přišla zpráva, že je v několikaměsíčním zpoždění s vydáním nové vlajkové AI verze Geminy Pro 3.5. V prostředí velké konkurence to může mít neblahý efekt ztráty poptávky. Akcie Alphabet končí silnou ztrátou –4,43 %.

Nevalný výsledek zažil i čipový sektor, kde velkou váhu poklesu má na svědomí Micron -5,65 % či AMD -5,33 %.

Oproti tomu se dařilo defenzivním sektorům spotřebního zboží či služeb. McDonald přidal slušných +3,04 %, PepsiCo též +2,97 % a například kartová asociace Mastercard +3,04 %.

Ropa WTI stále mírně ztrácela -0,75 %. Negativní vývoj na burze tedy dnes nebyl ovlivněn negativní geopolitickou situací.

Index Dow Jones -0,2 % na 52553,62 b.
S&P 500 -0,51 % na 7533,89 b.
Nasdaq Composite -1,47 % na 25881,95 b.

Index S&P 500 -0,51 % na 7533,89 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Nezbytná spotřeba +2,9 % Komunikační služby -2,8 % Zdravotní péče +2,2 % Informační technologie -1,8 % Reality +2,1 % Zbytná spotřeba -0,3 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Abbott Laboratories (ABT) +11 % Sandisk Corp (SNDK) -13 % JB Hunt Transport Services (JBHT) +8,0 % Seagate Technology Holdings (STX) -10,0 % Fedex Freight Holding (FDXF) +7,5 % Corning (GLW) -9,2 % Erie Indemnity (ERIE) +7,5 % Western Digital Corp (WDC) -9,2 % Dexcom (DXCM) +7,2 % Marvell Technology (MRVL) -8,7 %
Jan Pazourek, Fio banka, a.s.

-

Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days5.

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes.

Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM which is clinically proven to lower A1C and increase time in range6-10, Dexcom G7 15 Day sets a new standard in CGM technology that’s easy to use, painless to insert* and requires fewer sensor changes per month.

Diabetes is a complex and challenging condition that affects more than four million Canadians11 and requires around-the-clock management of glucose levels and decision‑making to manage safely.

“Small improvements can make a meaningful difference for people living with diabetes. Dexcom G7 15 Day reflects our ongoing commitment to simpler, more seamless diabetes management,” said André Côté, Vice President and General Manager, Dexcom Canada.

New with Dexcom G7 15 Day:

Longest lasting CGM system with 15.5 days of wear.5 Best-in-class accuracy with an overall MARD of 8.0%.1-4 Easier glucose management with fewer monthly sensor changes and reduced waste. Dexcom G7 features included with Dexcom G7 15 Day:

The only waterproof† CGMs available Direct to Apple Watch‡ connectivity, so you can leave your phone behind and still see your glucose numbers. 12-hour grace period to replace finished sensors for a more seamless transition between sessions. Innovative and simple mobile app with Dexcom Clarity integration to easily view glucose patterns, trends and statistics for meaningful conversations with your healthcare provider.§ Ability to remotely share glucose numbers with caregivers and loved ones for added support and peace of mind. ||,12 Customizable alert settings for improved discretion and personalized diabetes management. While authorized by Health Canada, Dexcom G7 15 Day is not yet available for purchase. André Côté shares, “Our focus is on ensuring that when the product becomes available, Canadians living with diabetes and their healthcare providers have the support, education, and experience they need from day one. We look forward to sharing more details as we move closer to availability.”

Visit Dexcom.com to get started with Dexcom G7 today, and register your details to opt in and receive information when Dexcom G7 15 Day becomes available.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

Category: IR

* 96% of patients reported mild/no pain.

† The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed.

‡ Smart devices sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch.

§ An internet connection is required for users to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity.

|| Separate Dexcom Follow app and internet connection required. Users should always confirm readings on the Dexcom G7 app or receiver before making treatment decisions.

1 Garg SK, et al. Diabetes Technol Ther. 2025;27(6):413-502.

2 Dexcom G7 15 Day User Guide.

3 FreeStyle Libre 3+ User Manual.

4 Medtronic Guardian Sensor User Guide.

5 Dexcom, Data on File, 2025.

6 Beck RW, et al. JAMA. 2017;317(4):371-378.

7 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.

8 Martens T, et al. JAMA. 2021;325(22):2262-2272.

9 Laffel LM, et al. JAMA. 2020;323(23):2388-2396.

10 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147.

11 Diabetes Canada. Diabetes in Canada. https://www.diabetes.ca/advocacy-policies/advocacy-reports/national-and-provincial-backgrounders/diabetes-in-canada. Accessed May 7, 2026.

12 Polonsky WH, Fortmann AL. Diabetes Technol Ther. 2021;23(3):195-202.

More News From DexCom, Inc.

Back to Newsroom

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.

Key Takeaways DexCom sees CGM expansion, G7 15 Day adoption and global growth supporting future performance.DXCM expanded non-insulin coverage, while low CGM penetration leaves room for multiyear growth.DexCom faces risks from CMS timing, input cost inflation and a maturing U.S. CGM market. DexCom, Inc. (DXCM - Free Report) is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performance and a robust international foothold are expected to contribute further. Risks related to stiff competition persist.

This Zacks Rank #3 (Hold) company’s shares have gained 7.3% so far this year against the industry’s 12.4% decline. The S&P 500 Index has gained 9.4% in the same time frame.

DXCM, a renowned medical device company and provider of CGM systems, has a market capitalization of $27.49 billion. It projects a 23.6% growth rate over the next five years and anticipates maintaining a strong performance going forward.

DexCom’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 9.37%.

Image Source: Zacks Investment Research

Let’s delve deeper.

Positive DriversType 2 Non-Insulin Expansion Represents Untapped Growth Opportunity: DexCom's biggest long-term catalyst remains the rapid expansion of CGM into the type 2 diabetes population not using insulin. During the quarter, the company expanded commercial coverage to more than 7 million non-insulin lives through the addition of Prime Therapeutics and reiterated that CMS reimbursement may start soon.

Management also expects the upcoming randomized controlled trial to reinforce the strong real-world evidence showing meaningful A1c reductions, potentially accelerating payer adoption globally. Since only about 30% of currently covered patients are using CGM, penetration remains low despite expanding reimbursement. If Medicare coverage eventually follows commercial payers, DexCom would gain access to millions of additional patients, creating a durable multiyear volume growth engine rather than a short-term sales catalyst.

G7 15-Day Launch Strengthens Competitive Position: The successful rollout of the Dexcom G7 15 Day system represents more than a routine product refresh. Longer wear time, improved sensor algorithms and better reliability are already driving higher customer satisfaction, stronger new patient starts and conversion of existing users.

Management expects nearly 50% of the installed base to migrate to the 15-day platform by year-end, improving customer retention while supporting manufacturing efficiencies. The launch also reinforces DexCom's ability to compete on product innovation rather than pricing, an increasingly important differentiator as the CGM market becomes more competitive.

Combined with upgraded adhesive technology, AI-powered software enhancements and Smart Basal functionality, DexCom is building a comprehensive ecosystem that could improve customer value while strengthening physician preference over competing platforms.

Robust Growth in International Markets: International operations continue to diversify DexCom's growth profile, reducing dependence on the mature U.S. diabetes market. International revenues grew 26% reportedly and 17% on an organic basis, driven by reimbursement expansion in markets such as France and Canada, while management highlighted additional payer wins expected throughout 2026.

Rather than relying on a single flagship product, DexCom is tailoring multiple products (including Stelo and a new CGM platform) to different reimbursement systems and customer segments across Europe and Asia-Pacific. This portfolio strategy is helping the company win tenders, convert previously exclusive contracts into dual-source agreements and steadily gain market share. As reimbursement expands globally, international markets could remain one of DexCom's fastest-growing businesses over the next several years.

RisksUncertain CMS Reimbursement Decisions: Although management repeatedly expressed confidence that Medicare reimbursement for non-insulin type 2 patients is inevitable, the timing remains entirely outside the company's control. Management acknowledged that CMS could impose eligibility requirements before approving coverage, while investors continue to view the decision as a major binary catalyst.

Because the opportunity represents one of DexCom's largest future growth drivers, any prolonged regulatory delay would postpone patient adoption, physician prescribing and revenue acceleration. Even if coverage is eventually approved, implementation timing and reimbursement criteria could influence the pace of uptake. Consequently, a meaningful portion of DexCom's long-term growth narrative still depends on external reimbursement decisions that management cannot directly influence.

Rising Input Cost Inflation Threatens Further Margin Expansion: Despite reporting excellent first-quarter profitability, DexCom deliberately maintained its gross margin guidance because of growing geopolitical uncertainty. Management estimates that rising oil prices, resin costs and freight expenses could create a 50-100 basis point gross margin headwind during the remainder of 2026.

Since CGM sensors rely heavily on petroleum-derived materials and global logistics, sustained commodity inflation could offset manufacturing productivity gains. While operational execution currently remains strong, prolonged geopolitical disruptions affecting shipping routes or raw material availability may pressure production costs and delay further margin expansion. As DexCom continues ramping up manufacturing capacity globally, maintaining cost discipline will become increasingly important for preserving profitability.

U.S. CGM Market Growth May Moderate as Penetration Matures: Although DexCom reported a global record for new patient additions, management acknowledged that U.S. patient starts were only close to a record, highlighting the increasingly mature nature of the domestic CGM market. Several analysts questioned whether overall U.S. market growth is slowing as major reimbursement expansions become less frequent.

Management's guidance also assumes continued coverage gains and sustained patient acquisition momentum throughout the year. If physician adoption slows or newly covered populations convert more gradually than anticipated, domestic revenue growth could remain below historical double-digit levels. This makes continued innovation, broader reimbursement and higher patient retention increasingly critical for sustaining DexCom's long-term growth trajectory.

Estimate TrendDexCom has witnessed a positive estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for 2026 earnings per share has moved north 1 cent to $2.57.

The consensus mark for the company’s second-quarter revenues is pegged at $1.3 billion, indicating an 11.9% improvement from the year-ago quarter’s reported number. The consensus estimate for second-quarter earnings is pinned at 61 cents per share, implying an improvement of 25% year over year.  

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.26%.

West Pharmaceutical, currently carrying a Zacks Rank #2, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.37%.

Intuitive Surgical, carrying a Zacks Rank of 2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.3% compared with the industry’s 12.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market. DXCM aims to expand CGM adoption to Type 2 non-insulin patients, but commercial uptake remains unproven despite positive clinical trial results. At 28x earnings, DXCM's valuation is not demanding, yet offers limited upside given execution risks and the need for evidence of new market penetration.

Key Takeaways DexCom will roll out its redesigned Stelo app in the United States starting in July.Stelo is expected to launch in four international markets later this year, with more expansion to 2027.DexCom gained FDA clearance for Stelo use in children aged 2 and older who are not using insulin. DexCom (DXCM - Free Report) recently announced that it will begin rolling out its fully reimagined Stelo app experience in the United States starting in July. The updated app, available for Apple iPhone and Android users, is designed to make glucose insights more accessible and actionable for individuals seeking to better understand their metabolic health.

Alongside the app launch, DexCom reiterated its plans to expand Stelo internationally. The platform is expected to launch in the United Kingdom, Australia, New Zealand and South Korea later this year, with further expansion continuing into 2027. The updates were highlighted as part of a broader set of milestones shared by the company at Aspen Ideas: Health.

Per management, glucose is relevant to everyone, and a better understanding of glucose patterns can help prevent serious health complications. The company is working to expand access to glucose biosensing to bring preventive, personalized care closer to reality and make the Stelo app experience more approachable with real-time insights that help people act earlier, before disease takes hold.

Likely Trend of DXCM Stock Following the NewsFollowing the announcement, DXCM shares lost 0.2% at yesterday’s closing. Year to date, the stock has gained 3.8% against the industry’s 18.3% decline. The S&P 500 has risen 7.4% in the same timeframe.

The rollout of the redesigned Stelo app and the planned international expansion may strengthen DexCom’s position in the growing glucose monitoring and metabolic health market. By enhancing the user experience and extending access to new geographic markets, the company is broadening the appeal of its Stelo platform beyond traditional diabetes management. The developments could support long-term revenue growth while reinforcing DexCom’s leadership in glucose biosensing technology.

DXCM currently has a market capitalization of $26.65 billion.

Image Source: Zacks Investment Research

More on the NewsThe reimagined Stelo app has been developed to help users better understand how everyday factors such as food, physical activity, sleep and stress affect their glucose levels and overall well-being. The updated experience aims to simplify glucose data and provide insights that are easier to interpret and act upon, supporting the growing shift toward preventive and personalized healthcare.

In addition to the app rollout, DexCom highlighted the recent FDA clearance of the Stelo for pediatric use. The recent clearance expanded its indication from adults aged 18 and older not using insulin to include children aged 2 years and older who are not using insulin. The approval comes as youth-onset Type 2 diabetes and metabolic syndrome continue to rise in the United States, providing families with greater access to glucose insights and improving metabolic health awareness from an early age.

Industry Prospects Favoring the MarketGoing by the data provided by Grandview Research, the continuous glucose monitoring (CGM) devices market was valued at $15.47 billion in 2026 and is expected to witness a CAGR of 15.1% through 2033.

Factors like the growing cases of diabetes, the increasing adoption of CGM devices, growing clinical needs, technological innovation and shifting care models are boosting the market’s growth.

Other NewsAt the recent Investor Day event, DexCom unveiled its next-generation CGM, the Dexcom G8 system, which is expected to be launched in late 2027 or early 2028. Features include step change improvement in glucose performance, a 50% smaller form factor than Dexcom G7 and advanced sensing capabilities.

DXCM’s Zacks Rank & Key PicksDexCom currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .

BrightSpring Health, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank stocks here.

BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: DexCom (DXCM - Free Report) San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.

DXCM is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. DXCM has a Growth Style Score of A, forecasting year-over-year earnings growth of 23.4% for the current fiscal year.

10 analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.09 to $2.58 per share. DXCM also boasts an average earnings surprise of +9.4%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, DXCM should be on investors' short list.

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Purchase Licensing Rights, opens new tab

CompaniesJune 12 (Reuters) - The U.S. Food and Drug Administration said on Friday it has expanded the ​use of Dexcom's (DXCM.O), opens new tab Stelo Glucose Biosensor ‌System to children with diabetes, making it the first over-the-counter continuous glucose monitor for pediatric use.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

The ​device is cleared for patients aged ​two years and older who do not ⁠use insulin. The FDA had previously ​cleared Stelo for adults aged 18 and ​older in March 2024.

Stelo uses a wearable sensor and smartphone app to track glucose levels, showing readings ​and trends every 15 minutes. Each sensor ​can last up to 15 days, though wear time ‌may ⁠be shorter in children, the FDA said.

The device can help children and caregivers understand how meals, exercise and lifestyle changes affect ​glucose levels, ​the agency ⁠said.

The FDA said children should use the device under adult ​supervision, and users should consult a ​healthcare ⁠provider before changing medication based on its readings.

The device is not meant for people with ⁠problematic ​low blood sugar, as ​it is not designed to alert users about that ​potentially dangerous condition.

Reporting by Kunal Das in Bengaluru

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Dexcom (DXCM) is leveraging AI to drive operational efficiency and product innovation, positioning itself as a platform medical provider in CGM. DXCM achieved 300 basis points in operating margin improvement, with sustained cost savings and strong FCF margin outpacing healthcare equipment peers. Stelo CGM, built with Google AI, targets the large prediabetic market, offering significant customer base expansion potential without requiring a prescription.

Dexcom's continuous glucose monitoring system, Maryland, U.S., July 15, 2021. REUTERS/Hannah Beier Purchase Licensing Rights, opens new tab

CompaniesMay 26 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said on Tuesday some of its glucose sensors ​slated for destruction were instead stolen and ‌sold, prompting the company to warn users not to use products from two affected lots.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

Dexcom ​said the affected G7 sensors, from ​lot numbers 1725204004 and 1725069002, had been ⁠marked as scrap as they did ​not meet company standards.

The sensors were stolen ​during a destruction process and later sold by third parties, with Dexcom tracing sales to Pharmsource LLC, ​which is not an authorized distributor.

One ​of the affected lots may carry an increased risk ‌of ⁠skin infection, while the other lot has a higher chance of producing no readings at all, DexCom said.

The issue mainly affects ​users in ​the United ⁠States, and Dexcom said it is notifying customers and offering ​replacements.

Dexcom said there have been no ​reported ⁠severe adverse events linked to the stolen sensors.

The company said it is working with ⁠the ​U.S. Food and Drug ​Administration and other authorities to investigate the theft.

Reporting by Kunal ​Das in Bengaluru; Editing by Vijay Kishore

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: DexCom (DXCM - Free Report) San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.

DXCM is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. DXCM has a Growth Style Score of A, forecasting year-over-year earnings growth of 23% for the current fiscal year.

10 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.07 to $2.57 per share. DXCM boasts an average earnings surprise of +9.4%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, DXCM should be on investors' short list.

Equity markets are experiencing a healthy dose of volatility this year. Based on broader macroeconomic indicators (like rising inflation), things might not settle down anytime soon. Although many are avoiding equity markets as a result, long-term investors know that, whatever is going on, the secret to earning strong returns hasn't changed: Buy shares of top companies at reasonable prices, and hold onto them through thick and thin. In fact, there are plenty of attractive growth stocks with bright prospects to be had right now. Here are two of them: Meta Platforms (META +0.43%) and Dexcom (DXCM 0.45%).

Image source: The Motley Fool.

1. Meta Platforms Investors are worried about Meta Platforms' runaway capex spending, which might squeeze profits and margins if it doesn't pay off, just like the company's metaverse spending was largely a flop. Also, during the company's first quarter, it posted a surprise quarter-over-quarter decline in daily active users, which was 3.56 billion for the period, down from 3.58 billion in the fourth quarter.

That's why Meta Platforms is not performing well this year. However, the tech leader has attractive opportunities that could allow it to deliver strong returns through the next 10 years. Let's consider three of them. First, Meta Platforms' core advertising business remains strong, partly thanks to its work in artificial intelligence (AI). AI-powered algorithms are increasing engagement across its websites and apps and boosting ad sales. This is ongoing work at Meta Platforms that could continue to yield results.

Second, Meta Platforms is diving into agentic AI. The company is working toward a future where it has AI assistants across its apps that help users -- whether individuals or businesses -- achieve their goals much more effectively. This could further boost Meta's engagement and make it much easier for companies on its platforms to interact with their clients and meet their needs.

Today's Change

(

0.43

%) $

2.42

Current Price

$

570.85

Third, Meta Platforms is still ramping up its smart glasses business. The glasses themselves won't be significant profit drivers -- they will carry lower margins than Meta's ad business. However, the company could sell various subscriptions while still using the significant data it will have access to through these glasses to improve its advertising segment. So, AI glasses could be another meaningful opportunity for the company. If it can execute its strategy across this and other potential growth avenues, its spending will be more than justified. Regarding the company's recent sequential decline in daily users, Meta blamed internet issues in Iran and restrictions on WhatsApp in Russia.

My view is that these aren't problems that will plague Meta Platforms in the long run. The company's user growth should resume. And even at current levels, it has a larger user base than almost any other company on the planet, along with a strong competitive edge from the network effect. All these factors make Meta Platforms a stock worth buying on the dip and holding onto for a while.

2. Dexcom Though Dexcom encountered some challenges -- including product recalls and slower-than-expected top-line growth -- in recent years, the company may have turned things around. The stock recently jumped significantly because Elliott Investment Management, a famous activist investment firm, took a significant stake in the company and will help add two new members to its board of directors.

Some investors view this as a strong endorsement of Dexcom's prospects. That aside, Dexcom continues to post solid financial results. In the first quarter, the company's revenue grew by a healthy 15% year over year to $1.19 billion. Dexcom's adjusted earnings per share of $0.56 jumped by 75% compared to the year-ago period.

Today's Change

(

-0.45

%) $

-0.34

Current Price

$

74.91

Dexcom remains a top player in the market for continuous glucose monitoring (CGM) devices that help diabetes patients track their blood sugar levels in real time throughout the day. The company still sees a massive addressable market in this space, especially given its relatively new launch in the U.S. -- the Stelo -- that sells over-the-counter and targets even those with prediabetes, thereby significantly boosting its opportunity. In the U.S., Dexcom estimates that more than nine million patients are eligible for CGM coverage but have yet to opt for it.

Meanwhile, the company is working on newer, better products while also expanding its reach by entering new regions. Dexcom expects 10% organic revenue growth per year through 2030, and it could perform well long after, given the opportunities ahead. The stock still looks attractive at current levels, even after the recent rally.

[url="]DexCom, Inc.[/url] (NASDAQ: DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment

Key Takeaways DexCom sees growth from expanding CGM access, including potential Medicare coverage gains.DXCM posted strong Q1 momentum with G7 15 Day expansion and Stelo platform enhancements.DexCom's international revenue rose 26%, supported by reimbursement and market expansion. DexCom, Inc. (DXCM - Free Report) is well-positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performance and a strong international foothold are expected to contribute further. Risks related to stiff competition persist.

This Zacks Rank #3 (Hold) company’s shares have gained 8.2% so far this year against the industry’s 16.7% decline. The S&P 500 Index has gained 10.2% in the same time frame.

DXCM, a renowned medical device company and provider of CGM systems, has a market capitalization of $28.34 billion. It projects a 23.5% growth rate over the next five years and anticipates maintaining a strong performance going forward.

DexCom’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 9.37%.

Let’s delve deeper.

Image Source: Zacks Investment Research

Positive DriversExpanding Addressable Market: DexCom’s long-term growth trajectory is anchored in a significant expansion of its addressable market, particularly among type 2 non-insulin patients. Management highlighted that Medicare coverage for this population could unlock access for nearly 12 million additional patients, with private payer coverage already progressing.

Clinical evidence, registry data and upcoming randomized trial readouts further support adoption in this segment. Given strong utilization trends among early adopters, this expansion represents a structural demand driver that could sustain double-digit growth for multiple years.

Solid International Foothold: DexCom continues to focus on international markets, with an emphasis on Europe and other large diabetes geographies where CGM penetration remains low. In first-quarter 2026, international revenue increased 26% year over year on a reported basis and 17% on an organic basis, showing that demand and access expansion remain active outside the United States.

Management outlined a focused international strategy that targets additional market share gains through reimbursement progress and a portfolio that can be matched to local channels, including Dexcom One+ in Europe. The company expects the international launch of the G7 15 Day platform to begin in the second half of 2026, which should support retention and mix as longer wear time becomes the baseline across the product portfolio.

Strong Q1 Results: DexCom exited the first quarter of 2026 on a strong note, supported by solid revenue growth, margin expansion and continued momentum across its CGM portfolio. The company expanded the launch of its G7 15 Day system across all channels in the United States, receiving encouraging feedback from both patients and physicians due to improved accuracy, reliability and extended wear duration. Alongside hardware innovation, DexCom continues to enhance its digital ecosystem, introducing upgraded Smart Meal Logging features within its Stelo platform to drive deeper user engagement and personalization.

RisksCutthroat Competition: The market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions. Apart from DexCom, Medtronic and Abbott have received FDA clearance for CGM devices and continue to broaden their commercial reach. Abbott’s FreeStyle Libre franchise competes directly in type 1 and type 2 diabetes, while Medtronic and other third parties have developed, or are developing, insulin pumps integrated with CGM systems that can influence sensor choice in automated insulin delivery.

Some competitors are also developing invasive and non-invasive glucose testing technologies that have the potential to compete with DexCom’s products over time. Senseonics has received FDA clearance for its implantable CGM system, Eversense, with a usable life of up to 365 days, and is pursuing broader integration.

Estimate TrendDexCom has witnessed a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share has moved 3 cents north to $2.57.

The consensus mark for the company’s second-quarter revenues is pegged at $1.29 billion, indicating an 11.7% improvement from the year-ago quarter’s reported number. The consensus estimate for second-quarter earnings is pinned at 60 cents per share, implying an improvement of 25% year over year.  

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Dexcom's continuous glucose monitoring system, Maryland, U.S., July 15, 2021. REUTERS/Hannah Beier Purchase Licensing Rights, opens new tab

CompaniesJune 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type ​2 diabetes not using insulin, compared with routine care, according to ‌study results.

The results were presented on Saturday at the American Diabetes Association.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

Here are more details from the study:

The 26-week study tested 283 non-insulin using diabetic patients, of whom half were put on Dexcom's G7 ​and half used self-monitoring of blood glucose. Most participants were on common diabetes medication ​such as metformin, GLP-1s and SGLT2s.

Participants using the Dexcom G7 saw ⁠an average 1.6% reduction in their blood sugar levels at 26 weeks, a ​0.9% greater reduction than those who used self-monitoring.

"Our hope is that this will ​substantially influence (the standard of care) and it'll improve access for all people with type 2, including those not on insulin to CGMs," Tamara Oser, professor, at the University of Colorado Anschutz, and ​the study's principal investigator, told Reuters.

Continuous glucose monitors are wearable devices that track ​blood sugar without finger pricks. Rising awareness, broader insurance coverage and ease of use are ‌boosting adoption ⁠of devices like Dexcom's G7.

The study found that using Dexcom G7 further lowered blood sugar levels when combined with common diabetes medications.

Among participants using GLP-1 drugs, those using the Dexcom G7 saw a 1.4% drop in blood sugar levels, compared ​with a 0.2% reduction ​in the control ⁠group.

"...it proves without a doubt that there's significant benefit here for these users. I think both the clinical community as ​well as the health care system and payers, they will, ​with this ⁠type of result, recognize both the health benefits, as well as the economic benefit," Dexcom CEO Jake Leach told Reuters.

These results "will help establish a new standard of care ⁠in the ​U.S. and around the world," he said in ​a statement.

A six-month extension phase of the study is currently being conducted, which will provide data for ​up to 12 months.

Reporting by Sneha S K in Bengaluru; Editing by Shreya Biswas

Our Standards: The Thomson Reuters Trust Principles., opens new tab

DexCom Inc. (NASDAQ:DXCM) stock is trading higher on Monday after the diabetes management company reported positive results from its CONNECT randomized controlled trial.

On Saturday, the study showed that use of the Dexcom G7 continuous glucose monitoring (CGM) system led to clinically and statistically significant reductions in A1C and improved glucose control among adults with Type 2 diabetes who are not using insulin.

Researchers also observed additional A1C reductions when Dexcom G7 was used alongside standard diabetes treatments, including metformin, GLP-1 therapies, and SGLT2 inhibitors.

Key Findings From The CONNECT TrialParticipants using Dexcom G7 recorded an average A1C reduction of 1.6% from a baseline mean A1C of 8.8%, representing a 0.9% greater decline than the control group.

Among participants with starting A1C levels above 10%, the average reduction reached 3.1%, exceeding the control group by 2.1%.

Additionally, 82% of Dexcom G7 users achieved at least a 0.5% reduction in A1C. By week 26, 68% of participants reached an A1C below 7.5%, while 46% achieved levels below 7.0%.

Improved Time In Range And Patient SatisfactionThe study also showed meaningful improvements in glucose management. Participants using Dexcom G7 spent an average of five additional hours per day within the target glucose range of 70 to 180 mg/dL compared with the control group.

Improvements appeared within the first four weeks and were maintained throughout the study.

At the end of 26 weeks, Dexcom G7 users averaged 62% time in range versus 41% for those receiving routine care.

Participants also reported greater satisfaction with CGM use, lower diabetes-related distress, and reduced disease burden. Median daily use of the device reached 97% during the trial.

A six-month extension phase is underway to evaluate whether the observed benefits can be sustained for up to 12 months.

DXCM Stock Price Activity: DexCom shares were up 5.45% at $76.83 at the time of publication on Monday, according to Benzinga Pro data.

Photo: Photo Nature Travel / Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: DexCom (DXCM - Free Report) San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.

DXCM is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Medical stock. DXCM has a Momentum Style Score of A, and shares are up 27.9% over the past four weeks.

10 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.09 to $2.58 per share. DXCM boasts an average earnings surprise of +9.4%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, DXCM should be on investors' short list.